GlassScriptPhysician profile
Erica Dewitt
NPI 1962820688
$2,922.77
in general payments reported to CMS, 2019-2025
26 companies · $844 in 2025
The $844 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $483 · 2023: $845 · 2024: $751 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.32 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $395.13 | 2022-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $357.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $317.07 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Abbvie INC. | $237.14 | 2022-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $223.40 | 2022-2023 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $214.34 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $210.40 | 2022-2025 | |
| Astellas Pharma US INC | $162.14 | 2024-2025 | Veozah |
| Esperion Therapeutics, INC. | $130.96 | 2024-2025 | Nexletol |
| Boston Scientific Corporation | $130.44 | 2023 | Advantage System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.90 | 2022-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $82.48 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.12 | 2023-2025 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $36.69 | 2023 | Krystexxa |
| Abbott Laboratories | $35.07 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $32.58 | 2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $31.59 | 2025 | Zoryve |
| Corcept Therapeutics | $26.73 | 2025 | Korlym |
| Sanofi Pasteur INC. | $23.10 | 2023 | |
| Paratek Pharmaceuticals, INC. | $21.37 | 2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $18.47 | 2024 | Voquezna |
| Radius Health, INC. | $15.43 | 2025 | |
| Currax Pharmaceuticals LLC | $15.34 | 2024 | Onzetra Xsail, Contrave |
| Irhythm Technologies, INC. | $14.68 | 2024 | Zio Monitor, Zio Xt Patch |
| Xeris Pharmaceuticals, INC. | $14.15 | 2025 | Gvoke Hypopen |
| Genzyme Corporation | $13.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.